Grameva Q1 Results: Revenue up 560% YoY to ₹4,697 lakh
Grameva Limited posted strong Q1FY27 results with revenue soaring 560% YoY to ₹4,697.19 lakh, while net profit grew modestly by 3.9% to ₹68.07 lakh. The Board enhanced credit limits to ₹18.89 crore to support operations. Rising other expenses warrant monitoring as they outpaced revenue growth.

*this image is generated using AI for illustrative purposes only.
Grameva Limited reported a sharp expansion in top-line growth for the first quarter of FY27, driven by a substantial increase in operational activity. Revenue from operations surged to ₹4,697.19 lakh for the quarter ended June 30, 2026, compared to ₹713.08 lakh in the same period last year. This represents a year-on-year increase of approximately 560%, signaling a major shift in the company’s agro product business volume.
Despite the dramatic rise in sales, net profit for the quarter stood at ₹68.07 lakh, a modest 3.9% increase from ₹65.52 lakh in Q1FY26. The divergence between revenue and profit growth highlights the impact of higher operating expenses and inventory adjustments during the period.
Financial Performance Details
The company’s total income reached ₹4,723.85 lakh, supported by other income of ₹26.67 lakh. However, total expenses climbed to ₹4,630.20 lakh from ₹683.96 lakh in the prior year’s quarter. Key expense drivers included:
- Purchases of stock-in-trade: ₹4,296.43 lakh (up from ₹641.54 lakh)
- Changes in inventories: ₹21.86 lakh (compared to a negative ₹13.35 lakh previously)
- Other expenses: ₹234.06 lakh (up significantly from ₹18.35 lakh)
Profit before tax was recorded at ₹93.66 lakh, against ₹54.49 lakh in Q1FY25. Tax expenses totaled ₹25.59 lakh, including deferred tax liability of ₹3.59 lakh.
What the Numbers Show
A notable observation is the disproportionate rise in 'other expenses' relative to revenue growth. While revenue increased nearly sixfold, other expenses jumped more than tenfold, from ₹18.35 lakh to ₹234.06 lakh. This suggests that administrative or non-operational costs are scaling faster than core business activities, potentially pressuring margins in the near term if not managed efficiently.
Additionally, finance costs remained relatively stable at ₹21.84 lakh, indicating that the company has not significantly increased its debt burden despite the surge in working capital requirements reflected in higher purchases and inventory changes.
Board Approvals and Corporate Actions
During its meeting on August 14, 2026, the Board of Directors approved the unaudited financial results after review by the Audit Committee. The results were subjected to a limited review by Amit Ray & Co., the statutory auditors.
In a separate resolution, the Board approved an enhancement of credit facilities from ₹8.00 crore to ₹18.89 crore, vide Sanction Letter No.: AXIS-00000241732-CBG/SEG/Shakespeare Sarani 1/2026-27 dated July 28, 2026. This move may support the company’s expanded operational scale observed in the quarter.
The trading window for the quarter ending June 30, 2026, was closed as per regulatory norms, with reopening dates considered accordingly.
Historical Stock Returns for Grameva
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.76% | -5.48% | -11.20% | +37.50% | +143.30% | +530.82% |
How does Grameva plan to address the disproportionate rise in 'other expenses' to ensure net profit margins scale with revenue in upcoming quarters?
What specific operational initiatives or market expansions are driving the 560% year-on-year revenue surge, and are these growth drivers sustainable?
Will the enhanced credit facility of ₹18.89 crore be utilized primarily for working capital to support inventory buildup, or for long-term capacity expansion?


































